Vaxcyte, Inc. — Director's Dealing 2020

Jun 18, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2020-06-16

Reporting Person: EMSTER KURT VON (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-06-16	Common Stock, $0.001 par value per share	C	2185415	—	Acquired	2185415	Indirect
2020-06-16	Common Stock, $0.001 par value per share	C	1217074	—	Acquired	3402489	Indirect
2020-06-16	Common Stock, $0.001 par value per share	C	454812	—	Acquired	3857301	Indirect
2020-06-16	Common Stock, $0.001 par value per share	C	298917	—	Acquired	4156218	Indirect
2020-06-16	Common Stock, $0.001 par value per share	P	12500	$16.00	Acquired	4168718	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-06-16	Series A Preferred Stock	$	C	2185415	Disposed		Common Stock, $0.001 par value per share (2185415)	Indirect
2020-06-16	Series B Preferred Stock	$	C	1217074	Disposed		Common Stock, $0.001 par value per share (1217074)	Indirect
2020-06-16	Series C Preferred Stock	$	C	454812	Disposed		Common Stock, $0.001 par value per share (454812)	Indirect
2020-06-16	Series D Preferred Stock	$	C	298917	Disposed		Common Stock, $0.001 par value per share (298917)	Indirect

Footnotes

F1: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F2: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

F3: Each share of Series A, Series B, Series C and Series D Preferred Stock was convertible into shares of Common Stock, $0.001 par value per share ("Common Stock") on a one-for-one basis with no expiration date and automatically converted into Common Stock upon the closing of the initial public offering.